Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Xencor (XNCR)

Xencor preliminary year-end cash about $707 million, up from $697.0 million in 2023

Positive Impact 3 of 5 earnings Written later

Xencor said its preliminary, unaudited cash, cash equivalents and marketable debt securities were about $707 million at December 31, 2024, compared with $697.0 million a year earlier. The company expects this cash to fund research and development and operations into 2028, and the figures may change after year-end closing and audit procedures.

Key points

  • Preliminary, unaudited cash, cash equivalents and marketable debt securities of about $707 million at December 31, 2024, versus $697.0 million at December 31, 2023
  • Based on current operating plans, Xencor expects cash to fund research and development programs and operations into 2028
  • January 13, 2025 investor presentation also updated XmAb808 to resumed dose escalation and reported completed enrollment in three vudalimab studies

The filing

CompanyXencor (XNCR)
Form8-K, current report
Filed with the SECJan 13, 2025, 8:08 AM ET
Accession number0001326732-25-000002

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 13, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.